Navigation Links
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Date:6/1/2011

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /PRNewswire/ -- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing. In preclinical studies, in vivo and in vitro activity has been demonstrated against multiple tumor types, including those resistant to other anti-cancer agents.

The NKP-1339 Phase I trial is a dose-ascending trial and determines the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of NKP-1339. A total of 16 patients with metastatic solid tumors resistant to standard therapies have been treated to date at six different dose levels. NKP-1339 treatment has been generally well tolerated, with the most common drug related side effects of grade 1-2 fever and mild flu-like symptoms. MTD has not been reached and NKP-1339 dose escalation continues. Signs of anti-tumor activity (stable disease greater than or equal to four months; tumor regression) have been observed. A patient with a neuroendocrine tumor (NET) of the small intestine has been on NKP-1339 therapy for over 13 months with a continuing minor response. The patient remains on NKP-1339 therapy. Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.

The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Translational Genomics Institute, Arizona, and Dr. Howard Burris, Sarah Canon Research Institute, Tennessee. Reflecting on NKP-1339's novel mechanism of action, Dr. Von Hoff noted "Resistance to anti-cancer therapy remains a major challenge in treatment of patients with metastatic cancer. First-
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
3. Novel Device Shows Promise for Reducing HIV Among Men
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
6. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
7. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... RIDGEFIELD, Conn. , Sept. 1, 2015  Results ... RE-VERSE AD™ study demonstrate that 5g of idarucizumab ... urgent situations involving patients treated with dabigatran (Pradaxa ... reversal of the anticoagulant effect of dabigatran enabled ... with a median time of 1.7 hours between ...
(Date:9/1/2015)... 2015 Sargas Pharmaceutical Adherence and Compliance ... Adherence m Health applications along with 24 hour ... non face-to-face monitoring of twenty minutes per month. ... our apps, doctors are now well prepared to ... ONCHIT certified Physician, Pharmacy and Patient portals that ...
(Date:9/1/2015)... 2015 The global ... of sectors, products & services and application. And the ... the increasing demand of advanced drugs for the ... the growth for bioinformatics market. The implementation of ... known as bioinformatics. Decreasing cost of DNA sequencing, ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4
... Clinic Discoveries is Developing Therapies for Wounds, Diabetic Foot ... , , GILROY, Calif., ... technology platform which employs nano-materials made of rare earth ... diabetic foot ulcers and hair growth are being developed ...
... one of the,largest studies of its kind, a multinational ... ) today report the discovery of common variations,at seven ... obesity. The study,analyzed more than 300,000 single-letter variations (SNPs) ... the Netherlands, and the United,States, and confirmed the findings ...
Cached Medicine Technology:OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 2OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 3Major deCODE-led Study Underscores Role of the Brain in Obesity 2Major deCODE-led Study Underscores Role of the Brain in Obesity 3Major deCODE-led Study Underscores Role of the Brain in Obesity 4Major deCODE-led Study Underscores Role of the Brain in Obesity 5
(Date:9/2/2015)... ... September 02, 2015 , ... Based ... GROUP is internationally known as an industry leader specializing in surplus used medical ... selling more than 100,000 pieces of medical equipment every year. Erik Tivin, Chairman ...
(Date:9/2/2015)... ... 2015 , ... “ G-Hold ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... a tablet while reducing the likelihood of it dropping. , Tablets like the iPad ...
(Date:9/2/2015)... NC (PRWEB) , ... September 02, 2015 , ... ... IT and business services, has been named to the Inc. 5000 List, an ... has been publishing this list for 34 years, and this achievement puts Canopy ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... reputation for the telling the truth about medicine and health, truths that other ... video blog, where he plans to regularly debunk certain misconceptions surrounding cholesterol, metabolically ...
(Date:9/1/2015)... Miami, FL (PRWEB) , ... September 01, 2015 ... ... Food and Drug Administration (FDA) for the treatment of androgenic alopecia in adults, ... the brand new laser therapy cap, while also demonstrating its safety when used ...
Breaking Medicine News(10 mins):Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2
... from around the world met at a conference in ... in obesity. One line of discussion looked at factors ... it might be avoided. , Co-chairs of the conference, ... Research and Dr Jennifer Lovejoy from the University of ...
... directed KH Real Estate to issue a boil water advisory to ... Armstrong County, after samples taken by DEP tested positive for fecal ... received complaints from residents after two customers were hospitalized with intestinal ... for the bacteria. , , ...
... NEW YORK, Nov. 24, 2008 Forest Laboratories, Inc. (NYSE: ... and Trademark Office ("USPTO") has closed prosecution on the merits ... confirmed the validity of all of the previously granted claims. ... Intent to Issue Ex Parte Reexamination Certificate for U.S. Patent ...
... treatment system for advanced radiation therapy, today announced that Rafael (Ralph) ... effective December 1, 2008. Mr. Vaello, who will report to TomoTherapy ... the sales and field marketing group for Philips Healthcare’s Oncology Imaging ... ...
... celebrity trainer Ramona Braganza offers tips to stay trim over the holidays and ... without packing on the pounds. , , ... trimmings: , , , ... before you load your plate for dinner or head out to a holiday ...
... of them currently abstain from alcohol, drugs , , MONDAY, ... Americans over the age of 12 participate in self-help ... 2.3 million who currently abstain from use of these ... Monday by the federal Substance Abuse and Mental Health ...
Cached Medicine News:Health News:Why women should eat less, move more and consider wearing transdermal HRT patches during menopause 2Health News:Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory 2Health News:USPTO Confirms Validity of Bystolic(R) Patent 2Health News: TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries 2Health News:Tip Sheet: Celebrity Trainer, Ramona Braganza's Tips To Keep Off Those Extra Holiday Pounds 2Health News:5 Million People a Year Use Self-Help Addiction Programs 2
... standard, corrected curve trial lenses are ground with ... Marco refractors and are invaluable in treating low ... other manufacturers contain a disproportionately large number of ... expensive to produce, and fewer lenses in the ...
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... has made the LM-770 the easiest ... Technicians can be trained to operate ... instruction. The instrument tells the user ... A flashing indicator alerts the user ...
... designed to perform precise and accurate ... one-third the space of traditional examinations. ... refractors, automatic or digital lensmeters and ... EPIC enables the operator to call ...
Medicine Products: